Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
PLUS THERAPEUTICS, Inc. (PSTV)
Company Research
Source: GlobeNewswire
HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced two new hires to its team for CNSide Diagnostics, LLC, its wholly-owned subsidiary. “We are strategically building the team to bolster our capabilities as we scale up our laboratory operations to address the largely untapped $6billion+ U.S. addressable market for CNSide cerebrospinal fluid assay for metastatic CNS cancers, all the while maintaining the highest quality standards,” said Russ Bradley, CNSide Diagnostics, LLC President and General Manager. “We continue our steady progress toward national launch and test coverage expansion, with plans for additional payor agreements to the previously announced agreements with UnitedHealthcare and Humana.” Two team members joining the CNSide Diagnostics team ar
Show less
Read more
Impact Snapshot
Event Time:
PSTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSTV alerts
High impacting PLUS THERAPEUTICS, Inc. news events
Weekly update
A roundup of the hottest topics
PSTV
News
- Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.MarketBeat
- Plus Therapeutics Expands CNSide Assay Platform to State of California [Yahoo! Finance]Yahoo! Finance
- Plus Therapeutics Expands CNSide Assay Platform to State of CaliforniaGlobeNewswire
- Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual MeetingGlobeNewswire
- Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.MarketBeat
PSTV
Earnings
- 8/14/25 - Beat
PSTV
Sec Filings
- 11/17/25 - Form 8-K
- 11/5/25 - Form 4
- 10/30/25 - Form 10-Q
- PSTV's page on the SEC website